Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Video Centre
Dr Olga Mikulich, Respiratory Consultant speaks about RSV and Arexvy
Protecting Adults At Increased Risk of RSV
Full video
RSV the Problem
Chapter 1 of 5
Arexvy: From Problem to Solution
Chapter 2 of 5
Safety of AREXVY
Chapter 3 of 5
Administration and Storage of AREXVY
Chapter 4 of 5
Dr Olga Mikulich's experience
Chapter 5 of 5
POM A. Marketing Authorisation Number: EU/1/23/1740/001-002. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.
PM-IE-RSA-WCNT-260003 Date of Preparation: July 2026
More videos coming soon.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
AREXVY is owned by or licensed to the GSK group of companies.
©2026 GSK group of companies or its licensor.
GlaxoSmithKline Biologicals S.A. Rixensart, Belgium.
PM-IE-RSA-WCNT-260002
Date of preparation: July 2026
